New approaches to modify glomerular inflammation

Journal of Nephrology

Volumn 12, Issue 2, 1999, Pages 66-75

  Kluth, David C ^a   Rees, Andrew J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Adhesion molecules; Chemokines; Glomerulonephritis; Interleukin 10; Interleukin 1; Interleukin 13; Interleukin 4; Interleukin 6; Macrophages; Transforming growth factor beta

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

CELL MIGRATION; GENE TRANSFER; GLOMERULONEPHRITIS; INFLAMMATION; INFLAMMATORY CELL; INHIBITION KINETICS; KIDNEY FAILURE; LEUKOCYTE ADHERENCE; MACROPHAGE; NEPHRITIS; PATHOGENESIS; REVIEW; TISSUE INJURY;

ANIMALS; CELL ADHESION; CHEMOTAXIS; GLOMERULONEPHRITIS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032973889     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Savill J, Rees AJ. Mechanisms of glomerular injury. In Oxford Textbook of Clinical Nephrology. AM Davison, JS Cameron, JP Grunfeld, DNS Kerr, E. Ritz, CG Winearls, editors. Oxford University Press, 1997; 403-39.
2. Kennedy J, Kelner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H, Schneider PV, Cocks BG, Bacon KB, Zlotnik A. Molecular cloning and functional characterization of human lymphotactin. J Immunol 1995; 155: 203-9.
3. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-4.
4. Baggiolini M, Chemokines and leukocyte traffic. Nature 1998; 392: 565-8.
5. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993; 365: 654-7.
6. Nishimura A, Akahoshi T, Takahashi M, Takagishi K, Itoman M, Kondo H, Takahashi Y, Yokoi K, Mukaida N, Matsushima K. Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8. J Leuk Biol 1997; 62: 444-9.
7. Feng L, Xia Y, Yoshimura T, Wilson CB. Modulation of neutrophil influx in glomerulonephritis in the rat with antimacrophage inflammatory protein-2 (MIP-2) antibody. J Clin Invest 1995; 95: 1009-17.
8. Tang WW, Qi M, Warren JS. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 1996; 50: 665-71 .
9. Chen S, Garcia GE, Bacon KB, Harrison JK, Wilson CB, Feng L. Prevention of CD8+ cell-mediated crescentic glomerulonephritis (GN) by inhibition of the CX3CR1, the fractalkine receptor. J Am Soc Nephrol 1998; 9: 473 (Abstr.)
10. Takano T, Brady HR. The endothelium in glomerular inflammation. Curr Opin Nephrol Hypert 1995; 4: 277-86.
11. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
12. Hill PA, Lan HY, Nikolic-Paterson DJ, Atkins RC. The ICAM-1/LFA-1 interaction in glomerular leukocytic accumulation in anti GBM glomerulonephritis. Kidney Int 1994; 45: 700-8.
13. Mulligan MS, Johnson KJ, Todd RF3, Issekutz TB, Miyasaka M, Tamatani T, Smith CW, Anderson DC, Ward PA. Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest 1993; 91: 577-87.
14. Tipping PG, Huang XR, Berndt MC, Holdworth SR. A role for P selectin in complement-independent neutrophil-mediated glomerular injury. Kidney Int 1994; 46: 79-88.
15. Nishikawa K, Guo YJ, Miyasaka M, Tamatani T, Collins AB, Sy MS, McCluskey RT, Andres G. Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J Exp Med 1993; 177: 667-77.
16. Kawasaki K, Yaoita E, Yamamoto T, Tamatani T, Miyasaka M, Kihara I. Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis. J Immunol 1993; 150: 1074-83.
17. Wu X, Tiwari AK, Issekutz TB, Lefkowith JB. Differing roles of CD18 and VLA-4 in leukocyte migration/activation during anti-GBM nephritis. Kidney Int 1996; 50: 462-72.
18. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
19. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med 1994; 45: 491-503.
20. Lake FR, Noble PW, Henson PM, Riches DW. Functional switching of macrophage responses to tumor necrosis factor-alpha (TNF alpha) by interferons. Implications for the pleiotropic activities of TNF alpha. J Clin Invest 1994; 93: 1661-9.
21. Slack J, McMahan CJ, Waugh S, Schooley K, Spriggs MK, Sims JE, Dower SK. Independent binding of interleukin-1a and interleukin 1b to type I and type II interleukin receptors. J Biol Chem 1993; 268: 2513-24.
22. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today 1994; 15: 562-6.
23. Nikolic-Paterson DJ, Lan HY, Atkins MB. Interleukin-1 receptor antagonism. Semin Nephrol 1996; 16: 583-90.
24. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. New Engl J Med 1996; 334: 1717-25.
25. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993; 43: 682-92.
26. Takemura T, Yoshioka K, Murakami K, Akano N, Okada M, Aya N, Maki S. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Archiv 1994; 424: 459-64.
27. Ardaillou R, Baud L. Tumor necrosis factor in glomerular injury. Contrib Nephrol 1996; 118: 59-67.
28. Tomosugi NI, Cashman SJ, Hay H, Pusey CD, Evans DJ, Shaw A, Rees AJ. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. Immunol 1989; 142: 3083-90.
29. Karkar AM, Koshino Y, Cashman SJ, Dash AC, Bonnefoy J, Meager A, Rees AJ. Passive immunization against tumour necrosis factor alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats. Clin Exp Immunol 1992; 90: 312-18.
30. Lan HY, Nikolic-Paterson DJ, Zarama M, Vannice JL, Atkins RC. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 1993; 43: 479-85.
31. Tang WW, Feng L, Vannice JL, Wilson CB. Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest 1994; 93: 273-79.
32. Karkar AM, Tam FW, Steinkasserer A, Kurrle R, Langner K, Scallon BJ, Meager A, Rees AJ. Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 1995; 48: 1738-46.
33. Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, Atkins RC. Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 1995; 47: 1303-9.
34. Karkar AM, Smith J, Pusey CD. Treatment of established nephrotoxic nephritis by neutralization of TNF-alpha. J Am Soc Nephrol 1998; 9: 478 (Abstr.)
35. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
36. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7: 145-73.
37. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist Proc Natl Acad Sci USA. 1992; 89: 4076-80.
38. Essner R, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857-61.
39. Ohmori Y, Smith MF, Hamilton TA. IL-4-induced expression of the IL-1 receptor antagonist gene is mediated by STAT6. J Immunol 1996; 157: 2058-65.
40. Colotta F, Saccani S, Giri JG, Dower SK, Sims JE, Introna M, Mantovani A. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J Immunol 1996; 156: 2534-41.
41. Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol 1996; 157: 3672-80.
42. Marfaing-Koka A, Devergne O, Gorgone G, Portier A, Schall TJ, Galanaud P, Emilie D. Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol 1995; 154: 1870-8.
43. Levesque MC, Haynes BF. Cytokine induction of the ability of human monocyte CD44 to bind hyaluronate is mediated primarily by TNF alpha and is inhibited by IL-4 and IL-13. J Immunol 1997; 159: 6184-94.
44. Abramson SL, Gallin JI. IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol 1990; 144: 625-30.
45. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines macrophage function and renders them unresponsive to other cytokines. J Immunol 1998; 161: 1983-8.
46. Bogdan C, Thuring H, Dlaska M, Rollinghoff M, Weiss G. Mechanism of suppression of macrophage nitric oxide release by IL-13: influence of the macrophage population. J Immunol 1997; 159: 4506-13.
47. Baud L, Fouqueray B, Bellocq A. Switching off renal inflammation by anti-inflammatory mediators: the facts, the promise and the hope. Kidney Int 1998; 53: 1118-26.
48. Holdsworth SR, Neale TJ, Wilson CB. Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest 1981; 68: 686-98.
49. DiPietro LA, Burdick M, Low QE, Kunkel SL, Strieter RM. MIP-1 alpha as a critical macrophage chemoattractant in murine wound repair. J Clin Invest 1998; 101: 1693-8.
50. Tam FW, Smith J, Karkar AM, Pusey CD, Rees AJ. Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor. Kidney Int 1997; 52: 1224-31.
51. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR. Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 1997; 27: 530-7.
52. Kitching AR, Tipping PG, Huang XR, Mutch DA, Holdsworth SR. Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice. Kidney Int 1997; 52: 52-9.
53. Huang XR, Tipping PG, Shuo L, Holdsworth SR. Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int 1997; 51: 94-103.
54. Santiago ML, Fossati L, Jacquet C, Muller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 1997; 185: 65-70.
55. Baumhofer JM, Beinhauer BG, Wang JE, Brandmeier H, Geissler K, Losert U, Philip R, Aversa G, Rogy MA. Gene transfer with IL 4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence. Eur J Immunol 1998; 28: 610-15.
56. Muchamuel T, Menon S, Pisacane P, Howard MC, Cockayne DA. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. J Immunol 1997; 158: 2898-903.
57. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996; 26: 2399-403.
58. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994; 56: 1-26.
59. Fouqueray B, Boutard V, Philippe C, Kornreich A, Marchant A, Perez J, Goldman M, Baud L. Mesangial cell-derived interleukin-10 modulates mesangial cell response to lipopolysaccharide. Am J Pathol 1995; 147: 176-82.
60. Pradier O, Gerard C, Delvaux A, Lybin M, Abramovicz D, Capel P, Velu T, Goldman M. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 1993; 23: 2700-3.
61. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, Mantovani A. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359-69.
62. Niemir ZI, Ondracek M, Dworacki G, Stein H, Waldherr R, Ritz E, Otto HF. In situ upregulation of IL-10 reflects the activity of human glomerulonephritides. Am J Kid Dis 1998; 32: 80-92.
63. Chadban SJ, Tesch GH, Lan HY, Atkins RC, Nikolic-Paterson DJ. Effect of interleukin-10 treatment on crescentic glomerulonephritis in rats. Kidney Int 1997; 51: 1809-17.
64. Baud L, Fouqueray B, Suberville S, Doublier S. Interleukin 10: a logical candidate for suppressing glomerular inflammation?. Exp Nephrol 1998; 6: 22-7.
65. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W KY mice. J Exp Med 1994; 179: 305-10.
66. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti inflammatory and immunosuppressive mediators. Immunol Today 1997; 18: 428-32.
67. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-7.
68. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113-8.
69. Hatzigeorgiou DE, He S, Sobel J, Grabstein KJ, Hafner A, Ho JL. IL-6 down-modulates the cytokine-enhanccd anti leishmanial activity in human macrophages. J Immunol 1993; 151: 3682-92.
70. Ikeda M, Ikeda U, Ohara T, Kusano E, Kano S. Recombinant interleukin-6 inhibits the growth of rat mesangial cells in culture. Am J Pathol 1992; 141: 327-34.
71. Horii Y, Iwano M, Hirata E, Shiiki M, Fujii Y, Dohi K, Ishikawa H. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int - Supplement 1993; 39: S71-115.
72. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Nad Acad Sci USA 1992; 89: 232-5.
73. Eitner F, Westerhuis R, Burg M, Weinhold B, Grone HJ, Ostendorf T, Ruther U, Koch KM, Rees AJ, Floege J. Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int 1997; 51 :69-78.
74. Karkar AM, Tam FW, Proudfoot AE, Meager A, Rees AJ. Modulation of antibody-mediated glomerular injury in vivo by interleukin-6. Kideny Int 1993; 44: 967-173.
75. Karkar AM, Smith J, Tam FW, Pusey CD, Rees AJ. Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6. Kidney Int 1997; 52: 1313-20.
76. Border WA, Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 1997; 51: 1388-96.
77. Del Giudice G, Crow MK. Role of transforming growth factor beta (TGF beta) in systemic autoimmunity. Lupus 1993; 2: 213-20.
78. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA. 1992; 89: 421-5.
79. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S. Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol 1990; 145: 940-4.
80. Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med 1993; 178: 605-13.
81. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature 1988; 334: 260-2.
82. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med 1987; 166: 571-6.
83. Wahl SM, Costa GL, Corcoran M, Wahl LM, Berger AE. Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 1993; 150: 3553-60.
84. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ, Keller and JR. Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med 1990; 172: 737-44.
85. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994; 266: F 829-42.
86. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994; 45: 916-27.
87. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA. 1993; 90: 1814-18.
88. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M. TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 1994; 45: 525-36.
89. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-9.
90. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta. Nature 1990; 346: 371-4.
91. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Yu, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360: 361-4.
92. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996; 2: 418-23.
93. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, Thorgeirsson SS. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74: 991-1003.
94. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol 1991; 146: 3012-17.
95. Qin L, Ding Y, Bromberg JS. Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell-mediated immunity. Hum Gene Ther 1996; 7: 1981-8.
96. Kitamura M, Burton S, English J, Kawachi H, Fine LG. Transfer of a mutated gene encoding active transforming growth factor-beta 1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int 1995; 48: 1747-57.
97. Imai E, Isaka Y. Strategies for gene transfer to the kidney. Kidney Int 1998; 53: 264-72.
98. Kitamura M, Suto TS. Transfer of genetically engineered macrophages into the glomerulus. Kidney Int 1997; 51: 1274-9.
99. Kluth DC, Erwig LP, Rees AJ. Glomerular gene transfer using macrophages transfected with adenovirus. Exp Nephrol 1998; 6: 158 (Abstr.).
100. Kluth DC, Erwig LP, Pearce WP, Anegon I, Rees AJ. IL-4 and IL-10 glomerular gene transfer using macrophages transfected with adenovirus. J Am Soc Nephrol 1998; 9: 479 (Abstr.).
101. Yokoo T, Ohashi T, Utsunomiya Y, Hirano K, Kawamura T, Eto Y, Hosoya T. Application of gene therapy for antibody induced glomerulonephritis using bone marrow derived vehicle cells. J Am Soc Nephrol 1998; 9: 490 (Abstr.).